<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced the FDA accepted for priority review a Biologics License Application for REGEN-COV to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The FDA assigned a target action date of April 13, 2022 and plans to hold an advisory committee meeting to discuss the application beforehand.
...read full article on Benzinga
